CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia

Yongyan Song, Miaoyun Zhao, Xiao Cheng, Jing Shen, Rituraj Khound, Kezhong Zhang, Qiaozhu Su

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Abstract: Metabolic inflammation is closely associated with hyperlipidemia and cardiovascular disease. However, the underlying mechanisms are not fully understood. The current study established that cAMP-responsive-element-binding protein H (CREBH), an acute-phase transcription factor, enhances very-low-density lipoprotein (VLDL) assembly and secretion by upregulating apolipoprotein B (apoB) expression and contributes to metabolic inflammation-associated hyperlipoproteinemia induced by TNFα, lipopolysaccharides (LPS), and high-fat diet (HFD) in mice. Specifically, overexpression of CREBH significantly induced mRNA and protein expression of apoB in McA-7777 cells. Luciferase assay further revealed that the presence of CREBH could significantly increase the activity of the apoB gene promoter. In contrast, genetic depletion of CREBH in mice resulted in significant reduction in expression of hepatic apoB mRNA. Challenging mice with an acute fat load led to upregulation of triglyceride (TG)-rich lipoprotein secretion in wild type mice, but not in CREBH-null mice. TNFα treatment activated hepatic CREBH expression, which in turn enhanced hepatic apoB biosynthesis and VLDL secretion. Metabolic inflammation induced by LPS or HFD also resulted in overproduction of apoB and hyperlipoproteinemia in wild type mice, but not in CREBH-null mice. This study demonstrates that CREBH could be a mediator between metabolic inflammation and hepatic VLDL overproduction in chronic metabolic disorders. This novel finding establishes CREBH as the first transcription factor that regulates apoB expression on the transcriptional level and the subsequent VLDL biosynthesis in response to metabolic inflammation. The study also provides novel insight into the pathogenesis of hyperlipidemia in metabolic syndrome. Key messages: CREBH mediates inflammatory signaling to VLDL overproduction in metabolic stress.Activation of CREBH in inflammation enhances mRNA and protein expression of apoB.CREBH presents a potential novel therapeutic target for hyperlipoproteinemia.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalJournal of Molecular Medicine
DOIs
StateAccepted/In press - Apr 28 2017

Fingerprint

Hyperlipoproteinemias
VLDL Lipoproteins
Carrier Proteins
Apolipoproteins B
Inflammation
Liver
High Fat Diet
Hyperlipidemias
Messenger RNA
Lipopolysaccharides
Transcription Factors
Physiological Stress
Luciferases
Lipoproteins
Triglycerides
Proteins
Cardiovascular Diseases
Up-Regulation

Keywords

  • ApoB
  • CREBH
  • Metabolic inflammation
  • Metabolic syndrome
  • TNFα
  • VLDL

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Cite this

CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia. / Song, Yongyan; Zhao, Miaoyun; Cheng, Xiao; Shen, Jing; Khound, Rituraj; Zhang, Kezhong; Su, Qiaozhu.

In: Journal of Molecular Medicine, 28.04.2017, p. 1-11.

Research output: Contribution to journalArticle

Song, Yongyan ; Zhao, Miaoyun ; Cheng, Xiao ; Shen, Jing ; Khound, Rituraj ; Zhang, Kezhong ; Su, Qiaozhu. / CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia. In: Journal of Molecular Medicine. 2017 ; pp. 1-11.
@article{104fb0b1117442e784f93d9088666d4c,
title = "CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia",
abstract = "Abstract: Metabolic inflammation is closely associated with hyperlipidemia and cardiovascular disease. However, the underlying mechanisms are not fully understood. The current study established that cAMP-responsive-element-binding protein H (CREBH), an acute-phase transcription factor, enhances very-low-density lipoprotein (VLDL) assembly and secretion by upregulating apolipoprotein B (apoB) expression and contributes to metabolic inflammation-associated hyperlipoproteinemia induced by TNFα, lipopolysaccharides (LPS), and high-fat diet (HFD) in mice. Specifically, overexpression of CREBH significantly induced mRNA and protein expression of apoB in McA-7777 cells. Luciferase assay further revealed that the presence of CREBH could significantly increase the activity of the apoB gene promoter. In contrast, genetic depletion of CREBH in mice resulted in significant reduction in expression of hepatic apoB mRNA. Challenging mice with an acute fat load led to upregulation of triglyceride (TG)-rich lipoprotein secretion in wild type mice, but not in CREBH-null mice. TNFα treatment activated hepatic CREBH expression, which in turn enhanced hepatic apoB biosynthesis and VLDL secretion. Metabolic inflammation induced by LPS or HFD also resulted in overproduction of apoB and hyperlipoproteinemia in wild type mice, but not in CREBH-null mice. This study demonstrates that CREBH could be a mediator between metabolic inflammation and hepatic VLDL overproduction in chronic metabolic disorders. This novel finding establishes CREBH as the first transcription factor that regulates apoB expression on the transcriptional level and the subsequent VLDL biosynthesis in response to metabolic inflammation. The study also provides novel insight into the pathogenesis of hyperlipidemia in metabolic syndrome. Key messages: CREBH mediates inflammatory signaling to VLDL overproduction in metabolic stress.Activation of CREBH in inflammation enhances mRNA and protein expression of apoB.CREBH presents a potential novel therapeutic target for hyperlipoproteinemia.",
keywords = "ApoB, CREBH, Metabolic inflammation, Metabolic syndrome, TNFα, VLDL",
author = "Yongyan Song and Miaoyun Zhao and Xiao Cheng and Jing Shen and Rituraj Khound and Kezhong Zhang and Qiaozhu Su",
year = "2017",
month = "4",
day = "28",
doi = "10.1007/s00109-017-1534-4",
language = "English (US)",
pages = "1--11",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - CREBH mediates metabolic inflammation to hepatic VLDL overproduction and hyperlipoproteinemia

AU - Song, Yongyan

AU - Zhao, Miaoyun

AU - Cheng, Xiao

AU - Shen, Jing

AU - Khound, Rituraj

AU - Zhang, Kezhong

AU - Su, Qiaozhu

PY - 2017/4/28

Y1 - 2017/4/28

N2 - Abstract: Metabolic inflammation is closely associated with hyperlipidemia and cardiovascular disease. However, the underlying mechanisms are not fully understood. The current study established that cAMP-responsive-element-binding protein H (CREBH), an acute-phase transcription factor, enhances very-low-density lipoprotein (VLDL) assembly and secretion by upregulating apolipoprotein B (apoB) expression and contributes to metabolic inflammation-associated hyperlipoproteinemia induced by TNFα, lipopolysaccharides (LPS), and high-fat diet (HFD) in mice. Specifically, overexpression of CREBH significantly induced mRNA and protein expression of apoB in McA-7777 cells. Luciferase assay further revealed that the presence of CREBH could significantly increase the activity of the apoB gene promoter. In contrast, genetic depletion of CREBH in mice resulted in significant reduction in expression of hepatic apoB mRNA. Challenging mice with an acute fat load led to upregulation of triglyceride (TG)-rich lipoprotein secretion in wild type mice, but not in CREBH-null mice. TNFα treatment activated hepatic CREBH expression, which in turn enhanced hepatic apoB biosynthesis and VLDL secretion. Metabolic inflammation induced by LPS or HFD also resulted in overproduction of apoB and hyperlipoproteinemia in wild type mice, but not in CREBH-null mice. This study demonstrates that CREBH could be a mediator between metabolic inflammation and hepatic VLDL overproduction in chronic metabolic disorders. This novel finding establishes CREBH as the first transcription factor that regulates apoB expression on the transcriptional level and the subsequent VLDL biosynthesis in response to metabolic inflammation. The study also provides novel insight into the pathogenesis of hyperlipidemia in metabolic syndrome. Key messages: CREBH mediates inflammatory signaling to VLDL overproduction in metabolic stress.Activation of CREBH in inflammation enhances mRNA and protein expression of apoB.CREBH presents a potential novel therapeutic target for hyperlipoproteinemia.

AB - Abstract: Metabolic inflammation is closely associated with hyperlipidemia and cardiovascular disease. However, the underlying mechanisms are not fully understood. The current study established that cAMP-responsive-element-binding protein H (CREBH), an acute-phase transcription factor, enhances very-low-density lipoprotein (VLDL) assembly and secretion by upregulating apolipoprotein B (apoB) expression and contributes to metabolic inflammation-associated hyperlipoproteinemia induced by TNFα, lipopolysaccharides (LPS), and high-fat diet (HFD) in mice. Specifically, overexpression of CREBH significantly induced mRNA and protein expression of apoB in McA-7777 cells. Luciferase assay further revealed that the presence of CREBH could significantly increase the activity of the apoB gene promoter. In contrast, genetic depletion of CREBH in mice resulted in significant reduction in expression of hepatic apoB mRNA. Challenging mice with an acute fat load led to upregulation of triglyceride (TG)-rich lipoprotein secretion in wild type mice, but not in CREBH-null mice. TNFα treatment activated hepatic CREBH expression, which in turn enhanced hepatic apoB biosynthesis and VLDL secretion. Metabolic inflammation induced by LPS or HFD also resulted in overproduction of apoB and hyperlipoproteinemia in wild type mice, but not in CREBH-null mice. This study demonstrates that CREBH could be a mediator between metabolic inflammation and hepatic VLDL overproduction in chronic metabolic disorders. This novel finding establishes CREBH as the first transcription factor that regulates apoB expression on the transcriptional level and the subsequent VLDL biosynthesis in response to metabolic inflammation. The study also provides novel insight into the pathogenesis of hyperlipidemia in metabolic syndrome. Key messages: CREBH mediates inflammatory signaling to VLDL overproduction in metabolic stress.Activation of CREBH in inflammation enhances mRNA and protein expression of apoB.CREBH presents a potential novel therapeutic target for hyperlipoproteinemia.

KW - ApoB

KW - CREBH

KW - Metabolic inflammation

KW - Metabolic syndrome

KW - TNFα

KW - VLDL

UR - http://www.scopus.com/inward/record.url?scp=85018247850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018247850&partnerID=8YFLogxK

U2 - 10.1007/s00109-017-1534-4

DO - 10.1007/s00109-017-1534-4

M3 - Article

SP - 1

EP - 11

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

ER -